HIGH INTENSITY HYPOLIPIDEMIC THERAPY AND DECREASED LEVEL OF LOW DENSITY LIPOPROTEIDES CHOLESTEROL: IS THE APPROACH JUSTIFIED? POINT OF VIEW
https://doi.org/10.15829/1560-4071-2018-6-191-201
Abstract
The review is focused on the issue of high-intensity treatment. The evidence provided, on efficacy of statins prescription in high intensity regimen to patients with very high cardiovascular risk. Indications outlined for this type of therapy in primary and secondary prevention practice. Problems of tolerability and safety also considered.
About the Author
M. G. Bubnova
National Research Center for Preventive Medicine of the Ministry of Health
Russian Federation
Russian Federation
Moscow
References
1. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal 2017; 38: 2459-72. DOI: 10.1093/eurheartj/ehx144.
2. Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J 2015; 36: 539-50. DOI: 10.1093/eurheartj/eht571.
3. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Eur Heart J 2016; 37: 2999-3058. DOI: 10.1093/eurheartj/ehw272.
4. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1–Full Report J Clinical Lipidology 2015; 9: 129-69.DOI:10.1016/j.jacl.2015.02.003.
5. Ezhov MV, Sergienko IV, Aronov DM, et al. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations VI revision. JAD 2017; 3 (28): 5-22. (In Russ.)
6. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration, Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81. DOI: 10.1016/S0140-6736(10)61350-5.
7. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532-61. DOI: 10.1016/S01406736(16)31357-5.
8. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016; 316: 1289-97. DOI: 10.1001/jama.2016.13985.
9. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-8. PMID: 11277825.
10. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 N Engl J Med 2004; 350:.1495-504. DOI: 10.1056/NEJMoa040583.
11. Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005; 46: 1411-6. DOI: 10.1016/j.jacc.2005.04.064.
12. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372: 2387-97. DOI: 10.1056/NEJMoa1410489.
13. Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376: 1713-22. DOI: 10.1056/NEJMoa1615664.
14. Koskinas КC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials Eur Heart J 2018; 39; 1172-80. DOI: 10.1093/eurheartj/ehx566.
15. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007; 99: 410-4. DOI: 10.1016/j.amjcard.2006.08.051.
16. Hwang D, Kim HK, Lee JM, et al. The KAMIR Investigators. Effects of Statin Intensity on Clinical Outcome in Acute Myocardial Infarction Patients. Circ J 2018; 82: 1112-20. DOI: 10.1253/circj.CJ-17-1221.
17. Boekholdt SM, Hovingh GK, Mora S, et al. Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events A Meta-Analysis of Statin Trials JACC, 2014; 5: 485-94. DOI: 10.1016/j.jacc.2014.02.615.
18. Giugliano RP, Pedersen TR, Park JG, et al. FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017; 390: 1961-71. DOI: 10.1016/S0140-6736(17)32290-0.
19. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association Of Clinical Endocrinologists And American College Of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease — executive summary. Endocr Pract. 2017; 23 (4): 479-97. DOI: 10.4158/EP171764.GL.
20. Bertoluci MC, Moreira RO, Faludi A, et al. Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). Diabetol Metab Syndr. 2017; 9: 53. DOI: 10.1186/s13098-017-0251-z.
21. Ridker PM, Danielson E, Fonseca EAH, et al. Rosuvastatin to prevent vascular events in men women with elevated C-Reactive Protein. N Engl J Med. 2008; 359: 2195-207. DOI: 10.1056/NEJMoa0807646.
22. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin The JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 201; 157: 1666-75. DOI: 10.1016/j.jacc.2010.09.082.
23. Fernández-Friera L, Fuster V, López-Melgar B, et al. Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. J Am Coll Cardiol 2017; 70: 2979-91. DOI: 10.1016/j.jacc.2017.10.024.
24. Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISEIVUS trial. J Am Coll Cardiol 2015; 66: 495-507. DOI: 10.1016/j.jacc.2015.05.065.
25. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365: 2078-87. DOI: 10.1056/NEJMoa1110874.
26. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA 2004; 291: 1071-80. DOI: 10.1001/jama.291.9.1071.
27. Crouse III JR, Raichlen JS, Evans GW, et al. Effects of Rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical аtherosclerosis. The METEOR trial. JAMA 2007; 297: 1344-53. DOI: 10.1001/jama.297.12.1344.
28. Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients. The GLAGOV randomized clinical trial. JAMA 2016; 316: 2373-84. DOI: 10.1001/jama.2016.16951.
29. Kataoka Y, Hammadah M, Puri R, et al. Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. Atherosclerosis, 2015; 242: 490-5. DOI: 10.1016/j.atherosclerosis.2015.08.005.
30. Falk E, Nakano M, Bentzon JF, et al. Update on acute coronary syndromes: the pathologists’ view. Eur. Heart J. 2013; 34: 719-28. DOI: 10.1093/eurheartj/ehs411.
31. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions, Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1262-75.
32. Puri R, Nissen SE, Libby P, et al. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy, Circulation, 2013; 128: 2395-403. DOI: 10.1161/CIRCULATIONAHA.113.004243.
33. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol 2012; 60: 2631-9. DOI: 10.1016/j.jacc.2012.09.017.
34. Vallejo-Vaz AJ, Robertson M, Catapano AL, et al. LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up. Circulation, 2017; 136: 1876-91. DOI: 10.1161/CIRCULATIONAHA.117.027966.
35. Ference B. A naturally randomized trial comparing the effect of long-term exposure to LDL-C, lower SBP, or both on the risk of cardiovascular disease. European Society of Cardiology Congress 2016; August 29, 2016; Rome, Italy. Abstract 3163.
36. Descamps OS, Bruniaux M, Guilmot PF, et al. Lipoprotein concentrations in newborns are associated with allelic variations in their mothers. Atherosclerosis 2004; 172: 287-98. DOI: 10.1016/j.atherosclerosis.2003.11.002.
37. Chapman MJ. Animal lipoproteins: chemistry, structure, and comparative aspects. J Lipid Res 1980; 21: 789-853.
38. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science, 1986, 232, 34-47.
39. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781-90. DOI: 10.1016/S0140-6736(07)60716-8.
Review
For citations:
Bubnova M.G. HIGH INTENSITY HYPOLIPIDEMIC THERAPY AND DECREASED LEVEL OF LOW DENSITY LIPOPROTEIDES CHOLESTEROL: IS THE APPROACH JUSTIFIED? POINT OF VIEW. Russian Journal of Cardiology. 2018;(6):191-201. (In Russ.) https://doi.org/10.15829/1560-4071-2018-6-191-201
Views:
1040
Email this article 